Table 1 Demographics and baseline characteristics of participants.
Characteristic | T-DM1/P (n = 52) | THP (n = 45) | CONTROL (n = 31) |
|---|---|---|---|
Median age, yr (range) | 48 (33–72) | 47 (29–70) | 50 (29–71) |
Ethnicity, n (%) | |||
White | 42 (81%) | 37 (82%) | 25 (81%) |
African American | 4 (8%) | 4 (9%) | 2 (6%) |
Asian | 5 (10%) | 2 (4%) | 4 (13%) |
Other/mixed | 1 (2%) | 2 (4%) | 0 (0%) |
HR Status, n (%) | |||
Positive | 35 (67%) | 29 (64%) | 19 (61%) |
Negative | 17 (33%) | 16 (36%) | 12 (39%) |
Mammaprint, n (%) | |||
MP1 | 29 (56%) | 28 (62%) | 26 (84%) |
MP2 | 23 (44%) | 17 (38%) | 5 (16%) |
Median tumor size, cm (range) | 3.3 (1.5–12) | 3.4 (1.8–9) | 3.5 (1.3–11.7) |
Baseline node status, n (%) | |||
Palpable | 18 (35%) | 17 (38%) | 10 (32%) |
Non-palpable | 24 (46%) | 22 (49%) | 21 (68%) |
N/A | 10 (19%) | 6 (13%) | 0 (0%) |
HER2 qualifying test, n (%) | |||
IHC | 35 (67%) | 30 (67%) | 18 (58%) |
FISH | 17 (33%) | 15 (33%) | 13 (42%) |
HER2 IHC, n (%) | |||
IHC 3+ | 35 (67%) | 30 (67%) | 17 (55%) |
IHC 2+ | 10 (19%) | 8 (18%) | 6 (19%) |
IHC 1+ | 2 (4%) | 1 (2%) | 1 (3%) |
Not reported | 5 (10%) | 6 (13%) | 7 (23%) |
HER2 FISH, n (%) | |||
Positive | 29 (56%) | 25 (56%) | 15 (48%) |
Equivocal | 0 (0%) | 0 (0%) | 1 (3%) |
Negative | 1 (2%) | 0 (0%) | 1 (3%) |
Not reported | 22 (42%) | 20 (44%) | 14 (45%) |
HER2 TargetPrint, n (%) | |||
Positive | 39 (75%) | 32 (71%) | 18 (58%) |
Negative | 13 (25%) | 13 (29%) | 10 (32%) |
Not reported | 0 (0%) | 0 (0%) | 3 (10%) |
